<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Gasparri, Maria Luisa</dc:creator>
  <dc:creator>Gentilini, Oreste Davide</dc:creator>
  <dc:creator>Lueftner, Diana</dc:creator>
  <dc:creator>Kuehn, Thorsten</dc:creator>
  <dc:creator>Kaidar-Person, Orit</dc:creator>
  <dc:creator>Poortmans, Philip</dc:creator>
  <dc:date>2020-05-29</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Background: Corona Virus Disease 19 (COVID-19) had a worldwide negative impact on healthcare systems, which were not used to coping with  such pandemic. Adaptation strategies prioritizing COVID-19 patients included triage of patients and reduction or re-allocation of other services. The  aim of our survey was to provide a real time international snapshot of modifications of breast cancer management during the COVID-19 pandemic.  Methods: A survey was developed by a multidisciplinary group on behalf of European Breast Cancer Research Association of Surgical Trialists and  distributed via breast cancer societies. One reply per breast unit was requested. Results: In ten days, 377 breast centres from 41 countries  completed the questionnaire. RT-PCR testing for SARS-CoV-2 prior to treatment was reported by 44.8% of the institutions. The estimated time  interval between diagnosis and treatment initiation increased for about 20% of institutions. Indications for primary systemic therapy were modified in  56% (211/377), with upfront surgery increasing from 39.8% to 50.7% (p &lt; 0.002) and from 33.7% to 42.2% (p &lt; 0.016) in T1cN0 triple-negative and  ER-negative/HER2- positive cases, respectively. Sixty-seven percent considered that chemotherapy increases risks for developing COVID-19  complications. Fifty-one percent of the responders reported modifications in chemotherapy protocols. Gene-expression profile used to evaluate the  need for adjuvant chemotherapy increased in 18.8%. In luminal-A tumours, a large majority (68%) recommended endocrine treatment to postpone  surgery. Postoperative radiation therapy was postponed in 20% of the cases. Conclusions: Breast cancer management was considerably modified  during the COVID-19 pandemic. Our data provide a base to investigate whether these changes impact oncologic outcomes.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://n2t.net/ark:/12658/srd1319224</dc:identifier>
  <dc:identifier>https://susi.usi.ch/global/documents/319224</dc:identifier>
  <dc:identifier>https://susi.usi.ch/documents/319224/files/gasparri_breast_2020.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.breast.2020.05.006</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/ark/12658/srd1319224</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>CC BY-NC-ND</dc:rights>
  <dc:source>The breast. - 2020, vol. 52, p. 110-115</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Breast cancer</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Breast surgery</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Chemotherapy</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">COVID-19</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Radiation therapy</dc:subject>
  <dc:subject>info:eu-repo/classification/udc/616</dc:subject>
  <dc:title xmlns:ns6="xml" ns6:lang="en">Changes in breast cancer management during the Corona Virus Disease 19 pandemic : an international survey of the European Breast Cancer Research Association of Surgical Trialists (EUBREAST)</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
